Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03084014 · 1 trial · 1 indication
Any DLT event attributable to PF-03084014 during Cycle 1: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days or unable to deliver at least 80% of planned dose due to treatment-related toxicities; Grade 4 neutropenia \>7 days; febrile neutropenia; neutropenic infection; Grade \>=3 thrombocytopenia with bleeding
Any DLT attributable to PF-03084014 at 1st Cycle: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days; unable to deliver at least 80% of planned dose; absolute neutrophil count (ANC) \<1000/microliter (uL), or platelet count \<30,000/uL, or hemoglobin \<8 gram/deciliter (g/dL) in a bone marrow with \<5% blasts and no evidence of leukemia or abnormal dysplasia for \>42 days
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-03084014 | DRUG | 10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily |
Inclusion Criteria: * Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available * Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available * Men and women \>...
PF-03084014 is an investigational small molecule being studied for the treatment of neoplasms by histologic type, which refers to cancers classified by their tissue of origin. It is being developed by Pfizer, Inc. for oncology indications.
PF-03084014 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in the oncology therapeutic area.
PF-03084014 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of neoplasms by histologic type.
PF-03084014 has been studied in one clinical trial, NCT00878189, titled "A Trial In Patients With Advanced Cancer And Leukemia." This Phase 1 trial was completed and enrolled 72 participants in the United States and Italy.
PF-03084014 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT00878189, was a Phase 1 study in patients with advanced cancer and leukemia, but approval status has not been established.